Welcome to our dedicated page for Alerian MLP Index ETN SEC filings (Ticker: amjb), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on Alerian MLP Index ETN's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time EDGAR feed updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into Alerian MLP Index ETN's regulatory disclosures and financial reporting.
JPMorgan Chase & Co. and JPMorgan Chase Financial Company LLC offer notes linked to the S&P Risk Control Index Series that provide variable notional exposure to underlying S&P indices while targeting specific annualized volatilities. Each Index adjusts a daily "leverage factor" (0%–150%) to target volatility (examples: 5%, 8%, 10%) and deducts a daily notional financing cost; the S&P Global 100 risk control index also deducts a 0.50% per annum Index Deduction. The supplements and term sheets govern specific issuances; risks include the drag from financing costs and deductions, potential failure to meet target volatility, limited operating history for the Global 100 risk control index and dependency on SOFR or Effective Federal Funds Rate methodologies.
JPMorgan Chase & Co. and JPMorgan Chase Financial Company LLC filed a prospectus addendum dated April 17, 2026 that supersedes prior prospectuses and supplements dated on or before that date. The addendum permits these documents to be used for reopenings of notes and for market‑making transactions in notes originally issued under earlier prospectuses.
JPMorgan Chase & Co. and JPMorgan Chase Financial Company LLC publish an underlying supplement describing structured notes linked to a wide range of indices and ETFs, including equity, futures and commodity benchmarks and many named Funds. The supplement lists index methodologies, governance, licensing and risk disclosures and states that specific issuance terms will appear in separate terms supplements.
The document explains index constructions (e.g., price-weighted and free-float adjusted methods), eligibility and rebalancing rules for the named indices and clarifies that licensors make no warranties and bear no liability for the notes.
JPMorgan Chase & Co. and its subsidiary JPMorgan Chase Financial Company LLC file a prospectus supplement for Series E (JPMorgan Chase) and Series A (JPMorgan Financial) medium-term notes, warrants and units under Registration Statement Nos. 333-293684 and 333-293684-01. The supplement describes broad program terms, currency- and index-linked payment mechanics, payment and book-entry procedures, tax and withholding risks (including Section 871(m)), foreign-exchange risks, and limitations related to resolution regimes and loss-absorption in a resolution scenario. The board has authorized issuance under the registration statement with an aggregate initial public offering price not to exceed $130 billion for each registrant; context figures for outstanding series are provided in the supplement.
JPMorgan Chase & Co. and JPMorgan Chase Financial Company LLC publish a product supplement and related prospectus materials describing general terms for Interest Rate-Linked Notes and Interest Rate and Equity Index-Linked Notes. The supplement explains issuer/guarantor roles, payment mechanics (Determination/Observation/Payment Dates), interest and day‑count conventions, valuation of Underlyings (including Compounded SOFR and ICE Swap Rates), estimated value methodology, secondary market considerations and material risks, and directs investors to the relevant terms supplement for offering‑specific details. April 17, 2026 is shown as the supplement date.
JPMorgan Chase & Co. and JPMorgan Chase Financial Company LLC are offering notes linked in whole or in part to the J.P. Morgan Multi-Asset Index (MAX Index). The underlying supplement describes the Index methodology, constituents, rebalancing mechanics and risks, including a 1.00% per annum daily deduction and a target volatility threshold of 4%.
The Index is a notional, futures-based, momentum strategy that selects a monthly “Selected Portfolio” from up to 10 Constituents with weights in 5% increments and caps/floors on individual and asset-class exposure; calculation began live on November 18, 2022 and the Index base level was 100.00 on February 22, 1994. The supplement emphasizes rule discretion by JPMS, concentration, currency and futures risks, and that the notes are not bank deposits nor CFTC‑regulated instruments.
JPMorgan Chase & Co. and JPMorgan Chase Financial Company LLC propose notes linked to the J.P. Morgan Gold Excess Return Index, a notional index that tracks SPDR Gold Shares (GLD) returns less a daily notional financing cost tied to SOFR. The Index was set to 100.00 on April 2, 2018 and began live calculation on December 13, 2024. JPMS sponsors and calculates the Index and may amend rules, replace the Constituent, or terminate publication at its discretion. The notes are unsecured, not bank deposits, not FDIC insured and involve the risks described under Risk Factors, including drag from the SOFR-linked notional financing cost and potential market disruption or succession events affecting GLD or SOFR.
JPMorgan Chase & Co. and JPMorgan Chase Financial Company LLC offer notes linked to the J.P. Morgan Dynamic Blend℠ Index, a notional, rules-based index that dynamically allocates between a US large-cap equities futures index and a 2-year US Treasury futures index while targeting 3.0% annualized realized volatility. The Index level reflects weighted returns of the two portfolio constituents less a daily 0.95% per annum deduction. The Index is an excess-return, notional construct (no underlying assets are owned) maintained and calculated by J.P. Morgan Securities LLC; the Rules govern calculation, succession events, market disruptions, and discretionary adjustments. Term sheets or pricing supplements will specify the terms of any particular note issuance.
JPMorgan Chase & Co. and JPMorgan Chase Financial Company LLC publish a product supplement and terms framework for Interest Rate‑Linked Notes and Interest Rate and Equity Index‑Linked Notes. The supplement describes issuer/guarantor structures, payment mechanics (Determination/Observation/Payment Dates), interest calculation conventions, valuation methodology, estimated value vs. original issue price, secondary market considerations, hedging and conflicts of interest, benchmark transition mechanics and key risks including credit risk, liquidity risk and index‑related risks. The document references governing indentures and DTC book‑entry issuance and states JPMS is the usual calculation agent and market counterparty.
JPMorgan Chase & Co. and JPMorgan Chase Financial Company LLC offer structured notes linked to one or more Reference Stocks, Indices or Funds. Terms for each issuance (including Principal Amount, Determination Dates, Payment Dates, interest and maturity) are set in a separate relevant terms supplement. Payments depend on the specified Underlying(s) and may be zero; notes are unsecured, subject to the issuer/guarantor credit risk, and may be accelerated upon specified change‑in‑law or commodity hedging disruption events.
Estimated value at pricing uses an internal funding rate plus derivative valuation; secondary market prices may be lower than original issue price. The product supplement highlights material risks, hedging conflicts, limited liquidity and uncertain tax treatment.